The procurement documents are available for unrestricted and full direct access, free of charge at:
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
II.1.1) Title
Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)
II.1.2) Main CPV code
85100000
II.1.3) Type of contract
Services
II.1.4) Short description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.1.5) Estimated total value
Value excluding VAT:
69 970 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
Yes
Tenders may be submitted for one lot only
Maximum number of lots that may be awarded to one tenderer: 1
Lot No: 1
II.2.1) Title
Lot 1 - London (2 Sites)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKI
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with two (2) sites in London. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
17 470 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Lot 2 - East of England (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKH
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the East of England. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Lot 3 - South East (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKJ
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South East. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Lot 4 - South West (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKK
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 5
II.2.1) Title
Lot 5 - Midlands (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKF
UKG
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the Midlands. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 6
II.2.1) Title
Lot 6 - North East and Yorkshire (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKC
UKE
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North East and Yorkshire.<br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 7
II.2.1) Title
Lot 7 - North West (1 Site)
II.2.2) Additional CPV code(s)
85100000
II.2.3) Place of performance
NUTS code:
UKD
II.2.4) Description of the procurement
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
8 740 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
31/10/2025
End:
30/10/2030
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. <br/><br/>Lot 1: London (2 sites)<br/>Lot 2: East of England (1 site)<br/>Lot 3: South East (1 site)<br/>Lot 4: South West (1 site)<br/>Lot 5: Midlands (1 site)<br/>Lot 6: North East and Yorkshire (1 site)<br/>Lot 7: North West (1 site)<br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). <br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. <br/><br/>Link for the current NICE paperwork:<br/>https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdf<br/><br/>Providers must also;<br/>• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. <br/>• hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.<br/>• Have expertise in delivering and managing cellular therapies <br/>• Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.<br/>• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. <br/>• Be a Heamotopoietic Stem Cell Transplantation centre <br/><br/>Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.<br/><br/>To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/Welcome<br/><br/>Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: <br/>Phone: 0800 9956035<br/>E-mail: support-health@atamis.co.uk<br/><br/>The closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.<br/><br/>Atamis Project reference C41701<br/><br/>The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The decision maker of the award will be: NHS England